| 1 | vs. | 46,972 |
| 2 | mmhg/ | 4 |
| 3 | sv-1/3 | 4 |
| 4 | bacillamide | 3 |
| 5 | +/-10.3 | 2 |
| 6 | anti-golgi | 2 |
| 7 | mg/μg | 2 |
| 8 | â | 2 |
| 9 | şi | 2 |
| 10 | ≙ | 2 |
| 11 | +21.5° | 1 |
| 12 | +30.0° | 1 |
| 13 | -odi | 1 |
| 14 | /child-pugh | 1 |
| 15 | 000-patient | 1 |
| 16 | 27,468 | 1 |
| 17 | 27.6+/- | 1 |
| 18 | 3.19p | 1 |
| 19 | 31a | 1 |
| 20 | 366-47 | 1 |
| 21 | 500.0/usd | 1 |
| 22 | 823-35 | 1 |
| 23 | 826±4 | 1 |
| 24 | and〈 | 1 |
| 25 | approximatley | 1 |
| 26 | cesário | 1 |
| 27 | cholesterol-quintile | 1 |
| 28 | delgaet | 1 |
| 29 | dexamethasone-21-sodium-phosphate | 1 |
| 30 | distance-adjusted | 1 |
| 31 | down-shifted | 1 |
| 32 | kg/m2≤bmi | 1 |
| 33 | mcitc | 1 |
| 34 | microeq/kg | 1 |
| 35 | mnpces/2500 | 1 |
| 36 | months-and | 1 |
| 37 | months-os | 1 |
| 38 | months-pfs | 1 |
| 39 | mt/11 | 1 |
| 40 | natrium-fluoride-containing | 1 |
| 41 | nmoles/min/mg | 1 |
| 42 | noncommercial-noderivatives | 1 |
| 43 | o.d.with | 1 |
| 44 | onabotulinumtoxina/-6.7 | 1 |
| 45 | pm/42 | 1 |
| 46 | squat-from | 1 |
| 47 | tests/1000 | 1 |
| 48 | treatment-ratio | 1 |
| 49 | visit=day | 1 |
| 50 | zol/11 | 1 |
| 51 | ±122.4 | 1 |
| 52 | ，after | 1 |
| 1 | +/-10.3 | 2 |
| 2 | +21.5° | 1 |
| 3 | +30.0° | 1 |
| 4 | -odi | 1 |
| 5 | /child-pugh | 1 |
| 6 | 000-patient | 1 |
| 7 | 27,468 | 1 |
| 8 | 27.6+/- | 1 |
| 9 | 3.19p | 1 |
| 10 | 31a | 1 |
| 11 | 366-47 | 1 |
| 12 | 500.0/usd | 1 |
| 13 | 823-35 | 1 |
| 14 | 826±4 | 1 |
| 15 | and〈 | 1 |
| 16 | anti-golgi | 2 |
| 17 | approximatley | 1 |
| 18 | bacillamide | 3 |
| 19 | cesário | 1 |
| 20 | cholesterol-quintile | 1 |
| 21 | delgaet | 1 |
| 22 | dexamethasone-21-sodium-phosphate | 1 |
| 23 | distance-adjusted | 1 |
| 24 | down-shifted | 1 |
| 25 | kg/m2≤bmi | 1 |
| 26 | mcitc | 1 |
| 27 | mg/μg | 2 |
| 28 | microeq/kg | 1 |
| 29 | mmhg/ | 4 |
| 30 | mnpces/2500 | 1 |
| 31 | months-and | 1 |
| 32 | months-os | 1 |
| 33 | months-pfs | 1 |
| 34 | mt/11 | 1 |
| 35 | natrium-fluoride-containing | 1 |
| 36 | nmoles/min/mg | 1 |
| 37 | noncommercial-noderivatives | 1 |
| 38 | o.d.with | 1 |
| 39 | onabotulinumtoxina/-6.7 | 1 |
| 40 | pm/42 | 1 |
| 41 | squat-from | 1 |
| 42 | sv-1/3 | 4 |
| 43 | tests/1000 | 1 |
| 44 | treatment-ratio | 1 |
| 45 | visit=day | 1 |
| 46 | vs. | 46,972 |
| 47 | zol/11 | 1 |
| 48 | ±122.4 | 1 |
| 49 | â | 2 |
| 50 | şi | 2 |
| 51 | ≙ | 2 |
| 52 | ，after | 1 |
| 1 | 27.6+/- | 1 |
| 2 | vs. | 46,972 |
| 3 | mmhg/ | 4 |
| 4 | tests/1000 | 1 |
| 5 | mnpces/2500 | 1 |
| 6 | zol/11 | 1 |
| 7 | mt/11 | 1 |
| 8 | pm/42 | 1 |
| 9 | +/-10.3 | 2 |
| 10 | sv-1/3 | 4 |
| 11 | ±122.4 | 1 |
| 12 | 826±4 | 1 |
| 13 | 823-35 | 1 |
| 14 | onabotulinumtoxina/-6.7 | 1 |
| 15 | 366-47 | 1 |
| 16 | 27,468 | 1 |
| 17 | 31a | 1 |
| 18 | mcitc | 1 |
| 19 | down-shifted | 1 |
| 20 | distance-adjusted | 1 |
| 21 | months-and | 1 |
| 22 | 500.0/usd | 1 |
| 23 | bacillamide | 3 |
| 24 | cholesterol-quintile | 1 |
| 25 | dexamethasone-21-sodium-phosphate | 1 |
| 26 | microeq/kg | 1 |
| 27 | nmoles/min/mg | 1 |
| 28 | natrium-fluoride-containing | 1 |
| 29 | mg/μg | 2 |
| 30 | /child-pugh | 1 |
| 31 | o.d.with | 1 |
| 32 | -odi | 1 |
| 33 | anti-golgi | 2 |
| 34 | kg/m2≤bmi | 1 |
| 35 | şi | 2 |
| 36 | squat-from | 1 |
| 37 | cesário | 1 |
| 38 | treatment-ratio | 1 |
| 39 | 3.19p | 1 |
| 40 | ，after | 1 |
| 41 | noncommercial-noderivatives | 1 |
| 42 | months-pfs | 1 |
| 43 | months-os | 1 |
| 44 | delgaet | 1 |
| 45 | 000-patient | 1 |
| 46 | visit=day | 1 |
| 47 | approximatley | 1 |
| 48 | and〈 | 1 |
| 49 | â | 2 |
| 50 | ≙ | 2 |
| 51 | +30.0° | 1 |
| 52 | +21.5° | 1 |